

INFORMAZIONI PERSONALI

Prof. Emanuele Barbato, MD, PhD, FESC

POSIZIONE

Professore Ordinario di Cardiologia

Dipartimento di Scienze Biomediche Avanzate, Università di Napoli Federico II

ESPERIENZE PROFESSIONALI

Professore Associato di Cardiologia

Dipartimento di Scienze Biomediche Avanzate, Università di Napoli Federico II

Dirigente Medico

Centro di Ricerche Cardiovascolari Ospedale OLV, Aalst, Belgium

Dirigente Medico

Ospedale San Sebastiano di Caserta

Dirigente Medico

Ospedale Sant'Andrea Università La Sapienza, Roma

Dirigente Medico

Ospedale S. Cuore di Gesù Fatebenefratelli, Benevento

FORMAZIONE

Dottorato di Ricerca in Fisiopatologia Cardiovascolare

Università Tor Vergata, Roma

Clinical Research Fellowship in Cardiologia Interventistica

Centro di Ricerche Cardiovascolari Ospedale OLV, Aalst, Belgium

Specializzazione in Cardiologia (70/70 con lode)

Università di Napoli Federico II

Research Fellowship di breve durata Cardiologia Molecolare

Duke University Medical Center, NC, US

Laurea in Medicina e Chirurgia (110/110 con lode)

Università di Napoli Federico II

ABILITA' PERSONALI

Lingua madre Italiano

Altre lingue

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
Dutch	C1	C1	C1	C1	B1
French	B1	B1	A2	A2	A1

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

ATTIVITA' DIDATTICA

- (2017) ASN come Professore di Prima Fascia di Cardiologia (06/D1)
- (2017) ASN come Professore di Prima Fascia di Medicina Interna (06/B1)
- (2017) ASN come Professore di Prima Fascia di Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate (06/N1)
- Direttore e Docente dei Corsi per il trattamento delle lesioni coronariche altamente calcifiche (Rotablator Courses, Boston Scientific)
- Direttore e Docente dei Corsi per l'imaging intracoronarico con Tomografia Ottica Coerente (OCT courses, Abbott Vascular)
- Docente dei Corsi di fisiopatologia coronarica (FFR courses, Abbott Vascular)
- Coordinatore e Docente di diversi PCR Seminars
- Membro del "Clinical Practice Guidelines" della Società Europea di Cardiologia (2016-2018)
- Docente di Cardiologia presso il Corso di Laurea in Medicina e Chirurgia in lingua Italiana ed in lingua inglese, presso il Corso di Laurea di primo livello in Tecniche di Fisiopatologia Cardiovascolare, presso la Scuola di Specializzazione di Cardiologia dell'Università di Napoli Federico II
- Coordinatore del Dottorato di Ricerca Internazionale in "Cardiovascular Pathophysiology and Therapeutics" (www.cardiopath.eu) dell'Università di Napoli Federico II
- (2012) ASN come Professore di Seconda Fascia di Cardiologia (06/D1)
- Professore a contratto presso la Scuola di Specializzazione in Cardiologia della II Facoltà di Medicina e Chirurgia dell'Università "La Sapienza" di Roma– Direttore Prof. M. Volpe
- Professore a contratto per attività di ricerca presso la II Facoltà di Medicina e Chirurgia dell'Università "La Sapienza" di Roma
- Coordinatore per il Belgio della piattaforma ESC learning (2013-2014)

ATTIVITA' EDITORIALE

- European Heart Journal (Membro Internazionale dell'Editorial Board e Revisore)
- Journal of Cardiovascular Medicine (Editore Associato e Revisore)
- Journal of Cardiovascular Translational Research (Editore Associato e Revisore)
- PCR online (Editore Associato)
- Journal of the American College of Cardiology (Revisore)
- JACC Cardiovascular Interventions (Revisore)
- American Journal of Cardiology (Revisore)
- Hypertension (Revisore)

SOCIETA' SCIENTIFICHE

- Circulation Cardiovascular Interventions (Revisore)
- International Journal of Cardiology (Membro dell'Editorial Board e Revisore)
- Membro di European Association of Percutaneous Coronary Intervention
- Membro della Società Italiana di Cardiologia
- Membro della Società Italiana di Cardiologia Invasiva (SICI-GISE)
- Membro della Società Belga di Cardiologia
- 2011-2016: Membro del Comitato per il programma scientifico di EAPCI (European Association of Percutaneous Coronary Intervention)
- 2014-2016: Co-chair del Comitato per le Società Cardiache Nazionali dell'EAPCI
- 2013 -: Membro del Direttivo del Working Group Belga di Cardiologia Invasiva (BWGIC)
- 2016 -: Membro del Comitato per il programma scientifico della Società Italiana di Cardiologia Invasiva (SICI-GISE)
- 2011 -: Membro del Comitato del programma scientifico del PCR (Percutaneous Coronary Revascularization)
- 2016-2018: Chair del Comitato per le Società Cardiache Nazionali dell'EAPCI
- 2018 -: Segretario eletto nel Comitato Direttivo dell'EAPCI

ATTIVITA' DI RICERCA

- 2008-2014: Direttore della Ricerca Clinica del Centro di Ricerche Cardiovascolari Aalst, (Belgio)
 - Medcor trial (Principal Investigator)
 - FAME II trial (Membro dello Steering Committee)
 - Century II trial (Membro dello Steering Committee)
 - FP7: Prestige registry (partecipante all'interno del network dell'Università Cattolica di Lovanio)
 - Compare Absorb trial (Membro dello Steering Committee)
 - OPTI-STEMI trial (Principal Investigator): PRIN 2017PZY5K7
- Finanziamento MIUR: euro 565.558

MEMBRO DATA SAFETY MONITORING COMMITTEE

- Sadra Lotus Valve First-in-man study
- Apposition II trial
- Confirm trial
- Pioneer trial

MEMBRO CRITICAL EVENT COMMITTEE

- FAME trial
- E-Select registry
- Sadra Lotus Valve "First-in-man" study
- Presillion trial
- Apposition II trial
- Source XT registry

PREMI E RICONOSCIMENTI

- Cavaliere dell'Ordine della Stella d'Italia
- Premio William W. Parmley per giovani ricercatori dell'American College of Cardiology
- Premio William Harvey della Società Italiana di Cardiologia
- Fellow della Società Europea di Cardiologia
- Scholar in Cardiology della Società Europea di Cardiologia

RELAZIONI SU INVITO E
MODERAZIONI**6th Wroclaw Rotablator Meeting (Wroclaw, Poland - 2018):**

- Moderatore e Relatore su invito

European Bifurcation Club (Porto, Portugal 2017):

- Relatore su invito

Serbian Conference on Interventional Cardiology and Cardiovascular Imaging (Belgrade, Serbia – 2017):

- Relatore su invito

European Society of Cardiology (Barcelona, Spain - 2017):

- Moderatore

EuroPCR (Paris, France - 2017):

- Moderatore e Relatore su invito

EAPCI Summit (Nice, France - 2017):

- Lettura: Training and practicing Interventional Cardiology in Europe: ready for a systematic and structured data collection

TCT meeting (Washington, US - 2016):

- Lettura: FFR in the setting of CABG and AS/AVR/TAVR

EACTS meeting (Barcelona, Spain –2016):

- Lettura: Is the angiogram enough? The role of fractional flow reserve guided revascularisation in coronary artery bypass graft

European Society of Cardiology (Rome, Italy - 2016):

- Moderatore

EAPCI fellows course (Nice, France - 2016):

- Moderatore e Relatore su invito

EuroPCR meeting (Paris, France -2016):

- Moderatore e Relatore su invito

Coronary Physiology in the Catheterization Laboratory (10th Edition)(Nice, France – 2016):

- Moderatore e Relatore su invito

6èmes Journées Nationales du GACI (French Society of Interventional Cardiology)(Paris, France – 2016)

- Lettura: Pourquoi je veux implanter un stent biorésorbable?

European Society of Cardiology (London, UK - 2015):

- Moderatore e Relatore su invito

EAPCI fellows course (Nice, France - 2015):

- Moderatore e Relatore su invito

EuroPCR meeting (Paris, France –2015):

- Moderatore e Relatore su invito

Coronary Physiology in the Catheterization Laboratory (9th Edition)(Nice, France - 2015):

- Moderatore e Relatore su invito

AsiaPCR meeting (Singapore -2015):

- Moderatore e Relatore su invito

European Society of Cardiology (Barcelona, Spain – 2014):

- Lettura: Fractional flow reserve in complex coronary lesions

EuroPCR meeting (Paris, France -2014):

- Moderatore e Relatore su invito

Coronary microcirculation and heart disease: an international summit (Madrid, Spain - 2014):

- Relatore su invito

Italian Society of Cardiology (Rome, Italy – 2013):

- Lettura: “CMR: all in one”

Cardiometabolic Risk and Vascular Diseases – Meeting of ESC WG on Peripheral Circulation (Rome, Italy – 2013)

- Lettura: “Coronary stent choice”

European Society of Cardiology (Amsterdam, The Netherlands – 2013):

- Lettura: “Fractional Flow Reserve in stable and unstable patients: same level of evidence?”

- Lettura: “Use of coronary angiography in patients with stable ischemic heart disease”

- Moderatore di sessione di poster

Coronary Physiology in the Cathlab (Catanzaro, Italy – 2013):

- Lettura: “FFR in specific angiographic settings”

- Lettura: “No, intracoronary is an excellent alternative!”

EuroPCR (Paris, France – 2013):

- Lettura: “Clinical relevance of coronary chronic total occlusion”

- Moderatore della sessione “CTO: set up your strategy to achieve success while keeping it simple”

- Moderatore della sessione “Complex cardiovascular interventions and new techniques”

- Moderatore della sessione “All you need to know about treatment of CTO”

- Moderatore della sessione “Treatment of coronary CTO: Japan meets Europe”

- Moderatore della sessione “Left main and complex bifurcation stenting”

- Moderatore della sessione “Learning the technique: Rotational atherectomy”

Coronary Physiology in the Cathlab (Nice, France – 2013) – Meeting of ESC WG on Coronary Pathophysiology and Microcirculation

- Lettura: “Role of invasive imaging: IVUS, OCT”

- Lettura: “Pitfalls with pressure measurements”

- Moderatore della sessione “The diagnosis of ischemic heart disease”

- Moderatore della sessione “FFR in clinical practice”

Italian Society of Cardiology (Rome, Italy – 2012):

- Lettura William Harvey: “From anatomy to function: a paradigm shift in myocardial revascularization strategies”

- Lettura: “Identificazione non-invasiva delle placche vulnerabili”

FFR workshop (Budapest, Hungary – 2012):

- Lettura William Harvey: “How I approach the patient with angina”

- Lettura: “Concept and practical set-up of CFR, FFR and IMR”

European Society of Cardiology (Munich, Germany – 2012):

- Lettura: “Technical aspects and clinical indication of FFR”

- Lettura: “FFR should be performed in all patients with Multivessel Disease”

EuroPCR (Paris, France – 2012):

- Moderatore della sessione “TNT: treatment of left main and multivessel disease”

- Moderatore della sessione LTT “How to succeed with complex PCI”

Rome Cardiology Forum (Rome, Italy – 2012):

- Lettura: “The challenge of chronic total occlusion”

6th European Interventional Cardiology Fellows Course (London, UK – 2011):

- Lettura: "When and how to do and interpret FFR measurement"

EuroPCR (Paris, France – 2011):

- Lettura: "Which patients may be considered for hybrid procedures"

- Moderatore della sessione LTT "How to select material and equipment for PCI"

- Moderatore della sessione "Coronary CTO: current techniques"

Coronary Physiology in the Cathlab (Nice, France – 2011) – Meeting of ESC WG on Coronary Pathophysiology and Microcirculation

- Lettura: "Hyperemic stimuli"

- Moderatore della sessione "The diagnosis of coronary atherosclerosis"

European Society of Cardiology (Paris, France – 2011):

- Lettura: "FFR: focus on ACS"

- Moderatore della sessione "New applications of functional lesion assessment"

Italian Society of Cardiology (Rome, Italy – 2010):

- Lettura: "Clinical implication of platelet endothelium interaction"

- Lettura: "Treatment of diabetic patient with NSTEMI ACS"

5th European Interventional Cardiology Fellows Course (London, UK – 2010):

- Lettura: "When and how to do and interpret FFR measurement"

EuroPCR (Paris, France – 2010):

- Lettura: "Technical approach for PCI in left main – case presentation"

- Moderatore della sessione LTT "TNT: the best option for left main and multivessel disease coronary revascularization"

European Society of Cardiology (Paris, France – 2010):

- Lettura: "Which stable patient really needs intervention?"

South Africa Heart Congress (Sun City, South Africa – 2009):

- Lettura: "Assessing non-culprit stenoses in the setting of primary PCI"

- Lettura: "Integration of the FAME, Courage and Syntax trials"

4th European Interventional Cardiology Fellows Course (London, UK – 2009):

- Lettura: "Physiological assessment"

European Society of Cardiology (Barcelona, Spain – 2009):

- Lettura: "How can intracoronary pressure management help?"

French Society of Cardiology (Paris, France – 2008):

- Lettura: "Early invasive strategy is the best approach of NSTEMI-ACS: against"

ARTICOLI IN GIORNALI PEER-REVIEWED

1. Authors/Task Force Members, Aboyans V, Björck M, Brodmann M, Collet JP, Czerny M, De Carlo M, Naylor AR, Roffi M, Tendera M, Vlachopoulos C, Ricco JB; Task Force for the 2017 ESC Guidelines for the diagnosis and management of Peripheral Arterial Diseases, in collaboration with the ESVS, Document Reviewers, Widimsky P, Kolh P, Dick F, de Ceniga MV, Piepoli MF, Sievert H, Sulzenko J, Esc Committee For Practice Guidelines Cpg, Windecker S, Aboyans V, Agewall S, **Barbato E**, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Jung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL. Questions and Answers on Diagnosis and Management of Patients with Peripheral Arterial Diseases: A Companion Document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc

- Surg. 2018 Apr;55(4):457-464.
2. Di Serafino L, Bartunek J, Heyndrickx G, Dierickx K, Scognamiglio G, Tesorio T, De Bruyne B, Trimarco B, Wijns W, **Barbato E**. Macrophage migration inhibitory factor (MIF) is associated with degree of collateralization in patients with totally occluded coronary arteries. *Int J Cardiol*. 2018 Jul 1;262:14-19.
 3. Rossini R, Tarantini G, Musumeci G, Masiero G, **Barbato E**, Calabrò P, Capodanno D, Leonardi S, Lettino M, Limbruno U, Menozzi A, Marchese UOA, Saia F, Valgimigli M, Ageno W, Falanga A, Corcione A, Locatelli A, Montorsi M, Piazza D, Stella A, Bozzani A, Parolari A, Carone R, Angiolillo DJ; Italian Society of Interventional Cardiology (SICI-GISE); Italian Society for the Study of Haemostasis and Thrombosis (SISST); Italian Society of Anesthesia and Intensive Care Medicine(SIAARTI); Italian Society of Surgery (SIC); Italian Society for Cardiac Surgery (SICCH); Italian Society of Vascular and Endovascular Surgery (SICVE); Italian Society of Urology (SIU); Italian Orthopaedic Society (SIOT); Italian Society of Thoracic Surgeons (SICT); Italian Federation of Scientific Societies of Digestive System Diseases (FISMAD); Italian Society of Digestive Endoscopy (SIED); Italian Association of Hospital Gastroenterology and Digestive Endoscopy (AIGO); Italian Association of Gastroenterology and Digestive Endoscopy (SIGE); Italian Society of Maxillofacial Surgery (SICMF); Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE); Italian Society of Gynecology and Obstetrics (SIGO); Italian Society of Neurosurgery (SINch); Italian Association of Hospital Pulmonologist (AIPO); Italian Society of Periodontology (SIdP); Italian Society of Ophthalmology (SOI); Italian Association of Hospital Otorhinolaryngologist(AOOI); Italian Association of Hospital Surgeons (ACOI); Association of Obstetricians Gynecologists Italian Hospital (AOGOI). A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. *JACC Cardiovasc Interv*. 2018 Mar 12;11(5):417-434.
 4. Elias J, van Dongen IM, Råmunddal T, Laanmets P, Eriksen E, Meuwissen M, Michels HR, Bax M, Ioanes D, Suttrop MJ, Strauss BH, **Barbato E**, Marques KM, Claessen BEPM, Hirsch A, van der Schaaf RJ, Tijssen JGP, Henriques JPS, Hoebbers LP; EXPLORE investigators. Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. *Heart*. 2018 Feb 20. pii: heartjnl-2017-312698.
 5. Mangiacapra F, Colaïori I, Riccotti E, Creta A, Di Gioia G, Cavallari I, Bressi E, Capuano M, **Barbato E**, Di Sciascio G. Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis. *J Thromb Thrombolysis*. 2018 May;45(4):496-503.
 6. Mo Y, Penicka M, Di Gioia G, **Barbato E**, Ondrus T, Vanderheyden M, De Bruyne B, Bartunek J, Van Camp G. Resolving Apparent Inconsistencies Between Area, Flow, and Gradient Measurements in Patients With Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction. *Am J Cardiol*. 2018 Mar 15;121(6):751-757.
 7. Van't Veer M, Pijls NHJ, Hennigan B, Watkins S, Ali ZA, De Bruyne B, Zimmermann FM, van Nunen LX, **Barbato E**, Berry C, Oldroyd KG. Comparison of Different Diastolic Resting Indexes to iFR: Are They All Equal? *J Am Coll Cardiol*. 2017 Dec 26;70(25):3088-3096.
 8. Strisciuglio T, **Barbato E**, De Biase C, Di Gioia G, Cotugno M, Stanzione R, Trimarco B, Sciarretta S, Volpe M, Wijns W, Delrue L, Rubattu S. T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients. *J Cardiovasc Transl Res*. 2018 Feb;11(1):36-41.
 9. Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Muñoz DR, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, Roffi M, Alfieri O, Agewall S, Ahlsson A, **Barbato E**, Bueno H, Collet JP, Coman IM, Czerny M, Delgado V, Fitzsimons D, Folliguet T, Gaemperli O, Habib G, Harringer W, Haude M, Hindricks G, Katus HA, Knuuti J, Kolh P, Leclercq C, McDonagh TA, Piepoli MF, Pierard LA, Ponikowski P, Rosano GMC, Ruschitzka F, Shlyakhto E, Simpson IA, Sousa-Uva M, Stepinska J, Tarantini G, Tchétché D, Aboyans V. Corrigendum to '2017 ESC/EACTS Guidelines for the management of valvular heart disease' [*Eur J Cardiothorac Surg* 2017;52:616-664]. *Eur J Cardiothorac Surg*. 2017 Oct 1;52(4):832.
 10. Maeremans J, Kayaert P, Bataille Y, Bennett J, Ungureanu C, Haine S, Vandendriessche T, Sonck J, Scott B, Coussement P, Dendooven D, Pereira B, Frambach P, Janssens L, Debruyne P, Van Mieghem C, **Barbato E**, Cornelis K, Stammen F, De Vroey F, Vercauteren S, Drieghe B, Aminian A, Debrauwere J, Carlier S, Coosemans M, Van Reet B, Vandergoten P, Dens JA; (On behalf of the BWGCTO Investigators). Assessing the landscape of percutaneous coronary chronic total occlusion treatment in Belgium and Luxembourg: the Belgian Working Group on Chronic Total Occlusions (BWGCTO) registry. *Acta Cardiol*. 2017 Nov 28:1-10.
 11. Ciccarelli G, **Barbato E**, Toth GG, Gahl B, Xaplanteris P, Fournier S, Milkas A, Bartunek J, Vanderheyden M, Pijls N, Tonino P, Fearon WF, Jüni P, De Bruyne B. Angiography Versus Hemodynamics to Predict the Natural History of Coronary Stenoses: Fractional Flow Reserve

- Versus Angiography in Multivessel Evaluation 2 Substudy. *Circulation*. 2018 Apr 3;137(14):1475-1485.
12. Heyse A, Milkas A, Van Durme F, **Barbato E**, Lazaros G, Vanderheyden M, Bartunek J. Pitfalls in coronary artery stenosis assessment in takotsubo syndrome: The role of microvascular dysfunction. *Hellenic J Cardiol*. 2017 Nov 13. pii: S1109-9666(17)30439-6.
 13. Fearon WF, Nishi T, De Bruyne B, Boothroyd DB, **Barbato E**, Tonino P, Jüni P, Pijls NHJ, Hlatky MA; FAME 2 Trial Investigators. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). *Circulation*. 2018 Jan 30;137(5):480-487.
 14. Pyxaras SA, Adriaenssens T, **Barbato E**, Ughi GJ, Di Serafino L, De Vroey F, Toth G, Tu S, Reiber JHC, Bax JJ, Wijns W. In-stent fractional flow reserve variations and related optical coherence tomography findings: the FFR-OCT co-registration study. *Int J Cardiovasc Imaging*. 2018 Apr;34(4):495-502.
 15. Maeremans J, Verhaert D, Pereira B, Frambach P, Van Mieghem C, **Barbato E**, Willems E, Vrolix M, Dens J. One-year clinical and computed tomography follow-up after implantation of bioresorbable vascular scaffolds in patients with coronary chronic total occlusions. *Catheter Cardiovasc Interv*. 2017 Oct 25.
 16. Kobayashi Y, Johnson NP, Zimmermann FM, Witt N, Berry C, Jeremias A, Koo BK, Esposito G, Rioufol G, Park SJ, Nishi T, Choi DH, Oldroyd KG, **Barbato E**, Pijls NHJ, De Bruyne B, Fearon WF; CONTRAST Study Investigators. Agreement of the Resting Distal to Aortic Coronary Pressure With the Instantaneous Wave-Free Ratio. *J Am Coll Cardiol*. 2017 Oct 24;70(17):2105-2113.
 17. Mo Y, Van Camp G, Di Gioia G, **Barbato E**, Ondrus T, Casselman F, Vanderheyden M, De Bruyne B, Bartunek J, Penicka M. Aortic valve replacement improves survival in severe aortic stenosis with gradient-area mismatch. *Eur J Cardiothorac Surg*. 2018 Mar 1;53(3):569-575.
 18. Piroth Z, Toth GG, Tonino PAL, **Barbato E**, Aghlmandi S, Curzen N, Rioufol G, Pijls NHJ, Fearon WF, Jüni P, De Bruyne B. Response by Piroth et al to Letter Regarding Article, "Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation". *Circ Cardiovasc Interv*. 2017 Oct;10(10). pii: e005973.
 19. Strisciuglio T, Di Gioia G, Chatzikiyiakou S, Silva Garcia E, **Barbato E**, Geelen P, De Potter T. Left atrial volume computed by 3D rotational angiography best predicts atrial fibrillation recurrence after circumferential pulmonary vein isolation. *Int J Cardiovasc Imaging*. 2018 Mar;34(3):337-342.
 20. **Barbato E**, De Bruyne B. [Fractional flow reserve to establish the indication for and guide myocardial revascularization]. *G Ital Cardiol (Rome)*. 2017 Sep;18(9 Suppl 1):9S-10S.
 21. **Barbato E**, Shlofmitz E, Milkas A, Shlofmitz R, Azzalini L, Colombo A. State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses - from debulking to plaque modification, a 40-year-long journey. *EuroIntervention*. 2017 Aug 25;13(6):696-705.
 22. Piroth Z, Toth GG, Tonino PAL, **Barbato E**, Aghlmandi S, Curzen N, Rioufol G, Pijls NHJ, Fearon WF, Jüni P, De Bruyne B. Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation. *Circ Cardiovasc Interv*. 2017 Aug;10(8). pii: e005233.
 23. Pellicano M, Floré V, Ferrara A, Adjedj J, **Barbato E**, Wijns W. Edge effect after intracoronary beta radiation brachytherapy and bare metal stent implantation: the pathway for very late stent failure. *Minerva Cardioangiol*. 2018 Feb;66(1):126-127.
 24. Mangiacapra F, Sticchi A, **Barbato E**. Thrombus aspiration in primary percutaneous coronary intervention: still a valid option with improved technique in selected patients! *Cardiovasc Diagn Ther*. 2017 Jun;7(Suppl 2):S110-S114.
 25. Adjedj J, Xaplanteris P, Toth G, Ferrara A, Pellicano M, Ciccarelli G, Floré V, **Barbato E**, De Bruyne B. Visual and Quantitative Assessment of Coronary Stenoses at Angiography Versus Fractional Flow Reserve: The Impact of Risk Factors. *Circ Cardiovasc Imaging*. 2017 Jul;10(7). pii: e006243.
 26. Carnevale R, Pignatelli P, Frati G, Nocella C, Stanzione R, Pastori D, Marchitti S, Valenti V, Santulli M, **Barbato E**, Strisciuglio T, Schirone L, Vecchione C, Violi F, Volpe M, Rubattu S, Sciarretta S. C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. *Sci Rep*. 2017 Jun 19;7(1):3797.
 27. De Bruyne B, Fournier S, **Barbato E**. Real-Life Fractional Flow Reserve. *Circulation*. 2017 Jun 6;135(23):2252-2254.
 28. Dudek D, **Barbato E**, Baumbach A, Windecker S, Haude M. Current trends in structural heart interventions: an overview of the EAPCI registries. *EuroIntervention*. 2017 May 15;13(Z):Z11-Z13.
 29. **Barbato E**, Dudek D, Baumbach A, Windecker S, Haude M. Current trends in coronary interventions: an overview from the EAPCI registries. *EuroIntervention*. 2017 May 15;13(Z):Z8-Z10.

30. **Barbato E**, Dudek D, Baumbach A, Windecker S, Haude M. EAPCI registries: a first step towards systematic monitoring of European interventional cardiology practice. *EuroIntervention*. 2017 May 15;13(Z):Z6-Z7.
31. Di Gioia G, Scarsini R, Strisciuglio T, De Biase C, Zivelonghi C, Franco D, De Bruyne B, Ribichini F, **Barbato E**. Correlation between Angiographic and Physiologic Evaluation of Coronary Artery Narrowings in Patients With Aortic Valve Stenosis. *Am J Cardiol*. 2017 Jul 1;120(1):106-110.
32. Wiemer M, Stojkovic S, Samol A, Dimitriadis Z, Ruiz-Nodar JM, Birkemeyer R, Monsegu J, Finet G, Hildick-Smith D, Tresukosol D, Novo EG, Koolen JJ, **Barbato E**, Danzi GB; NOBORI 2 investigators. Erratum to: Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. *Cardiovasc Diabetol*. 2017 May 4;16(1):59.
33. Ciccarelli G, Mangiacapra F, Pellicano M, **Barbato E**. Correlation between serum uric acid levels and residual platelet reactivity in patients undergoing PCI. *Nutr Metab Cardiovasc Dis*. 2017 May;27(5):470-471.
34. De Bruyne B, Adjedj J, Xaplanteris P, Ferrara A, Mo Y, Penicka M, Floré V, Pellicano M, Toth G, **Barbato E**, Duncker DJ, Pijls NH. Saline-Induced Coronary Hyperemia: Mechanisms and Effects on Left Ventricular Function. *Circ Cardiovasc Interv*. 2017 Apr;10(4). pii: e004719.
35. Petronio AS, Capranzano P, **Barbato E**, Piazza N, Baumbach A, Haude M, Windecker S. Current status of transcatheter mitral valve therapy in Europe: results from an EAPCI survey (Part II). *EuroIntervention*. 2017 Mar 20;12(16):1934-1939.
36. Janssen PWA, Mol EA, Geene SMC, **Barbato E**, Ten Berg JM. Does percutaneous coronary stent implantation increase platelet reactivity? *Blood Rev*. 2017 Sep;31(5):271-275.
37. Wiemer M, Stoikovic S, Samol A, Dimitriadis Z, Ruiz-Nodar JM, Birkemeyer R, Monsegu J, Finet G, Hildick-Smith D, Tresukosol D, Novo EG, Koolen JJ, **Barbato E**, Danzi GB; NOBORI 2 investigators. Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. *Cardiovasc Diabetol*. 2017 Feb 10;16(1):23.
38. Strisciuglio T, Di Gioia G, Mangiacapra F, De Biase C, Delrue L, Pellicano M, Bartunek J, Vanderheyden M, Izzo R, Trimarco B, Wijns W, **Barbato E**. Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel. *Thromb Res*. 2017 Mar;151:72-73.
39. Gargiulo G, Stabile E, Ferrone M, **Barbato E**, Zimmermann FM, Adjedj J, Hennigan B, Matsumura M, Johnson NP, Fearon WF, Jeremias A, Trimarco B, Esposito G; CONTRST Study Investigators. Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study. *Cardiovasc Diabetol*. 2017 Jan 13;16(1):7.
40. Strisciuglio T, **Barbato E**. The fractional flow reserve gray zone has never been so narrow. *J Thorac Dis*. 2016 Nov;8(11):E1537-E1539.
41. Pellicano M, De Bruyne B, Toth GG, Casselman F, Wijns W, **Barbato E**. Fractional flow reserve to guide and to assess coronary artery bypass grafting. *Eur Heart J*. 2017 Jul 1;38(25):1959-1968.
42. Strisciuglio T, **Barbato E**. Rotational atherectomy: you will never regret using it but you often regret not having used it! *EuroIntervention*. 2016 Dec 20;12(12):1441-1442.
43. Ciccarelli G, **Barbato E**, Golino M, Cimmino G, Bartunek J, Di Serafino L, Di Girolamo D, De Bruyne B, Wijns W, Golino P. Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. *J Interv Cardiol*. 2017 Feb;30(1):5-15.
44. Izzo R, Losi MA, Stabile E, Lönnebakken MT, Canciello G, Esposito G, Barbato E, De Luca N, Trimarco B, de Simone G. Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients: The Campania Salute Network. *Hypertension*. 2017 Jan;69(1):136-142.
45. **Barbato E**, Toth GG, Johnson NP, Pijls NH, Fearon WF, Tonino PA, Curzen N, Piroth Z, Rioufol G, Jüni P, De Bruyne B. A Prospective Natural History Study of Coronary Atherosclerosis Using Fractional Flow Reserve. *J Am Coll Cardiol*. 2016 Nov 29;68(21):2247-2255.
46. Wijns W, **Barbato E**. Let's talk BIG DATA. *EuroIntervention*. 2016 Oct 20;12(9):1081-1082.
47. Henriques JP, Hoebbers LP, Råmunddal T, Laanmets P, Eriksen E, Bax M, Ioanes D, Suttorp MJ, Strauss BH, **Barbato E**, Nijveldt R, van Rossum AC, Marques KM, Elias J, van Dongen IM, Claessen BE, Tijssen JG, van der Schaaf RJ; EXPLORE Trial Investigators. Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial. *J Am Coll Cardiol*. 2016 Oct 11;68(15):1622-1632.
48. Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, **Barbato E**, van der Heijden LC, Reiber JH, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. *JACC Cardiovasc Interv*. 2016 Oct 10;9(19):2024-2035.
49. Milkas A, Van Mieghem C, Van Hoe L, **Barbato E**, De Bruyne B. The 'napkin-ring' constrictive

- pericarditis. *Eur Heart J Cardiovasc Imaging*. 2016 Dec;17(12):1436.
50. Mangiacapra F, Panaioli E, Colaioni I, Ricottini E, Lauria Pantano A, Pozzilli P, **Barbato E**, Di Sciascio G. Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). *Circulation*. 2016 Sep 13;134(11):835-7.
 51. Xaplanteris P, **Barbato E**, De Bruyne B. Catheter-based functional metrics of the coronary circulation. *J Nucl Cardiol*. 2017 Aug;24(4):1178-1189.
 52. **Barbato E**, Toth GG, De Bruyne B. Coronary-Artery Bypass Grafting. *N Engl J Med*. 2016 Sep 8;375(10):e22.
 53. van 't Veer M, Adjedj J, Wijnbergen I, Tóth GG, Rutten MC, **Barbato E**, van Nunen LX, Pijls NH, De Bruyne B. Novel monorail infusion catheter for volumetric coronary blood flow measurement in humans: in vitro validation. *EuroIntervention*. 2016 Aug 20;12(6):701-7.
 54. Toth GG, Johnson NP, Jeremias A, Pellicano M, Vranckx P, Fearon WF, Barbato E, Kern MJ, Pijls NH, De Bruyne B. Standardization of Fractional Flow Reserve Measurements. *J Am Coll Cardiol*. 2016 Aug 16;68(7):742-53.
 55. **Barbato E**. Editorial commentary: Fractional flow reserve-A diagnostic tool, a prognostic index. *Trends Cardiovasc Med*. 2017 Feb;27(2):121-122.
 56. Mangiacapra F, Conte M, Demartini C, Muller O, Delrue L, Dierickx K, Di Sciascio G, Trimarco B, De Bruyne B, Wijns W, Bartunek J, **Barbato E**. Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis. *Int J Cardiol*. 2016 Oct 1;220:629-33.
 57. Mangiacapra F, Di Gioia G, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Bartunek J, Wijns W, De Bruyne B, **Barbato E**. Effects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective PCI. *J Am Coll Cardiol*. 2016 Jul 12;68(2):235-7.
 58. Petronio AS, Capranzano P, **Barbato E**, Piazza N, Baumbach A, Haude M, Windecker S. Current status of transcatheter valve therapy in Europe: results from an EAPCI survey. *EuroIntervention*. 2016 Sep 18;12(7):890-5.
 59. Ferrara A, Di Gioia G, Strisciuglio T, Wijns W, **Barbato E**. Overview of the clinical trials on bioresorbable vascular scaffold. *Minerva Cardioangiol*. 2016 Aug;64(4):473-80.
 60. Diletti R, Tchetché D, **Barbato E**, Latib A, Farah B, van Geuns RJ, Colombo A, Fajadet J, van Mieghem NM. Bioresorbable scaffolds for treatment of coronary bifurcation lesions: Critical appraisal and future perspectives. *Catheter Cardiovasc Interv*. 2016 Sep;88(3):397-406.
 61. Johnson NP, Jeremias A, Zimmermann FM, Adjedj J, Witt N, Hennigan B, Koo BK, Maehara A, Matsumura M, **Barbato E**, Esposito G, Trimarco B, Rioufol G, Park SJ, Yang HM, Baptista SB, Chrysant GS, Leone AM, Berry C, De Bruyne B, Gould KL, Kirkeeide RL, Oldroyd KG, Pijls NHJ, Fearon WF. Continuum of Vasodilator Stress From Rest to Contrast Medium to Adenosine Hyperemia for Fractional Flow Reserve Assessment. *JACC Cardiovasc Interv*. 2016 Apr 25;9(8):757-767.
 62. Di Serafino L, Borgia F, Maeremans J, Pyxaras SA, De Bruyne B, Wijns W, Heyndrickx GR, Dens J, Di Mario C, **Barbato E**. Periprocedural Myocardial Injury and Long-Term Clinical Outcome in Patients Undergoing Percutaneous Coronary Interventions of Coronary Chronic Total Occlusion. *J Invasive Cardiol*. 2016 Oct;28(10):410-414.
 63. Di Gioia G, Pellicano M, Toth GG, Casselman F, Adjedj J, Van Praet F, Ferrara A, Stockman B, Degrieck I, Bartunek J, Trimarco B, Wijns W, De Bruyne B, Barbato E. Fractional Flow Reserve-Guided Revascularization in Patients With Aortic Stenosis. *Am J Cardiol*. 2016 May 1;117(9):1511-5.
 64. Toth GG, De Bruyne B, Rusinaru D, Di Gioia G, Bartunek J, Pellicano M, Vanderheyden M, Adjedj J, Wijns W, Pijls NH, **Barbato E**. Impact of Right Atrial Pressure on Fractional Flow Reserve Measurements: Comparison of Fractional Flow Reserve and Myocardial Fractional Flow Reserve in 1,600 Coronary Stenoses. *JACC Cardiovasc Interv*. 2016 Mar 14;9(5):453-9.
 65. Di Gioia G, Pellicano M, Toth GG, Casselman F, Adjedj J, Van Praet F, Stockman B, Degrieck I, Trimarco B, Wijns W, De Bruyne B, **Barbato E**. Clinical Outcome of Patients with Aortic Stenosis and Coronary Artery Disease Not Treated According to Current Recommendations. *J Cardiovasc Transl Res*. 2016 Apr;9(2):145-52.
 66. Lesiak M, Araszkievicz A, Grajek S, Colombo A, Lalmand J, Carstensen S, Namiki A, Tobaru T, Merkely B, Moreno R, **Barbato E**, Wijns W, Saito S. Long Coronary Lesions Treated With Thin Strut Bioresorbable Polymer Drug Eluting Stent: Experience From Multicentre Randomized CENTURY II Study. *J Interv Cardiol*. 2016 Feb;29(1):47-56.
 67. Casselman F, Van der Merwe J, Ferrara A, **Barbato E**. The present day potential role of fractional flow reserve-guided coronary artery bypass graft surgery. *J Thorac Cardiovasc Surg*. 2016 Apr;151(4):926-32.
 68. Adjedj J, De Bruyne B, Floré V, Di Gioia G, Ferrara A, Pellicano M, Toth GG, Bartunek J, Vanderheyden M, Heyndrickx GR, Wijns W, **Barbato E**. Significance of Intermediate Values of Fractional Flow Reserve in Patients With Coronary Artery Disease. *Circulation*. 2016 Feb

- 2;133(5):502-8.
69. Fracassi F, Niccoli G, Scalone G, Di Gioia G, Conte M, Bartunek J, Sgueglia GA, De Bruyne B, Montone RA, Wijns W, Crea F, **Barbato E**. Prognostic role of multiple biomarkers in stable patients undergoing fractional flow reserve-guided coronary angioplasty. *J Cardiovasc Med (Hagerstown)*. 2016 Sep;17(9):687-93.
 70. Maeremans J, Knaapen P, Stuijzand WJ, Kayaert P, Pereira B, **Barbato E**, Dens J. Antegrade wire escalation for chronic total occlusions in coronary arteries: simple algorithms as a key to success. *J Cardiovasc Med (Hagerstown)*. 2016 Sep;17(9):680-6.
 71. Legrand D, **Barbato E**, Chenu P, Magne J, Vrolix M, Wijns W, Legrand V; STIB investigators. The STIB score: a simple clinical test to predict clopidogrel resistance. *Acta Cardiol*. 2015 Oct;70(5):516-21.
 72. **Barbato E**, Barton PJ, Bartunek J, Huber S, Ibanez B, Judge DP, Lara-Pezzi E, Stolen CM, Taylor A, Hall JL. Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine. *J Cardiovasc Transl Res*. 2015 Nov;8(8):466-74.
 73. Adjedj J, Toth GG, Johnson NP, Pellicano M, Ferrara A, Floré V, Di Gioia G, **Barbato E**, Muller O, De Bruyne B. Intracoronary Adenosine: Dose-Response Relationship With Hyperemia. *JACC Cardiovasc Interv*. 2015 Sep;8(11):1422-30.
 74. van Nunen LX, Zimmermann FM, Tonino PA, **Barbato E**, Baumbach A, Engstrøm T, Klauss V, MacCarthy PA, Manoharan G, Oldroyd KG, Ver Lee PN, Van't Veer M, Fearon WF, De Bruyne B, Pijls NH; FAME Study Investigators. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. *Lancet*. 2015 Nov 7;386(10006):1853-60.
 75. Tocci G, **Barbato E**, Coluccia R, Modestino A, Pagliaro B, Mastromarino V, Giovannelli F, Berni A, Volpe M. Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. *Am J Hypertens*. 2016 Apr;29(4):509-18.
 76. Wijns W, Shite J, Jones MR, Lee SW, Price MJ, Fabbicocchi F, **Barbato E**, Akasaka T, Bezerra H, Holmes D. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. *Eur Heart J*. 2015 Dec 14;36(47):3346-55.
 77. Losi MA, Strisciuglio T, Stabile E, Castellano G, de Amicis V, Saccenti A, Maresca G, Santoro C, Izzo R, **Barbato E**, Esposito G, Trimarco B, Rapacciuolo A. Iatrogenic atrial septal defect (iASD) after MitraClip system delivery: The key role of PaO₂/FiO₂ ratio in guiding post-procedural iASD closure. *Int J Cardiol*. 2015 Oct 15;197:85-6.
 78. G Toth G, Pyxaras S, Mortier P, De Vroey F, Di Gioia G, Adjedj J, Pellicano M, Ferrara A, De Schryver T, Van Hoorebeke L, Verhegghe B, **Barbato E**, De Bruyne B, De Beule M, Wijns W. Single String Technique for Coronary Bifurcation Stenting: Detailed Technical Evaluation and Feasibility Analysis. *JACC Cardiovasc Interv*. 2015 Jun;8(7):949-59.
 79. Strisciuglio T, Di Gioia G, De Biase C, Esposito M, Franco D, Trimarco B, **Barbato E**. Genetically Determined Platelet Reactivity and Related Clinical Implications. *High Blood Press Cardiovasc Prev*. 2015 Sep;22(3):257-64.
 80. **Barbato E**, Carrié D, Dardas P, Fajadet J, Gaul G, Haude M, Khashaba A, Koch K, Meyer-Gessner M, Palazuelos J, Reczuch K, Ribichini FL, Sharma S, Sipötz J, Sjögren I, Suetsch G, Szabó G, Valdés-Chávarri M, Vaquerizo B, Wijns W, Windecker S, de Belder A, Valgimigli M, Byrne RA, Colombo A, Di Mario C, Latib A, Hamm C; European Association of Percutaneous Cardiovascular Interventions. European expert consensus on rotational atherectomy. *EuroIntervention*. 2015 May;11(1):30-6.
 81. **Barbato E**, Dudek D, Haude M, Esposito G, Mauri J, Petronio S, Stabile E, Meier P, Weidinger F, Kala P, Trillo R, Witkowski A, Cummins P, Baumbach A, Windecker S. Mapping interventional cardiology in Europe: proceedings of the 3rd Summit of the European Association of Percutaneous Cardiovascular Interventions. *EuroIntervention*. 2015 May;11(1):27-8.
 82. Mangiacapra F, Ricottini E, **Barbato E**, Demartini C, Peace A, Patti G, Vizzi V, De Bruyne B, Wijns W, Di Sciascio G. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score. *Circ Cardiovasc Interv*. 2015 May;8(5). pii: e002106.
 83. Mangiacapra F, Cavallari I, Ricottini E, Pellicano M, **Barbato E**, Di Sciascio G. High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. *Int J Cardiol*. 2015;190:124-5.
 84. **Barbato E**, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W. Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the

- MEDCOR trial. *Atherosclerosis*. 2015 Jun;240(2):351-4.
85. Mangiacapra F, Ricottini E, Di Gioia G, Peace A, Patti G, De Bruyne B, Wijns W, **Barbato E**, Di Sciascio G. Comparison among patients ≥ 75 years having percutaneous coronary angioplasty using drug-eluting stents versus bare metal stents. *Am J Cardiol*. 2015 May 1;115(9):1179-84.
 86. **Barbato E**, Wijns W. Are we ready for a new paradigm shift in percutaneous revascularization of chronically occluded vessels with well-developed collaterals?: from leaving 'em all to stenting 'em all. *JACC Cardiovasc Interv*. 2015 Feb;8(2):280-282.
 87. Pellicano M, Toth G, Di Gioia G, Rusinaru D, Wijns W, **Barbato E**, De Bruyne B, Degrieck I, Van Mieghem C. Unrecognized anomalous left circumflex coronary artery arising from right sinus of Valsalva: a source of perioperative complication. *J Cardiovasc Med (Hagerstown)*. 2016 Dec;17 Suppl 2:e228-e230.
 88. Toth GG, Toth B, De Vroey F, Di Serafino L, Pyxaras S, Rusinaru D, Di Gioia G, Pellicano M, **Barbato E**, Van Mieghem C, Heyndrickx GR, De Bruyne B, Wijns W, Johnson NP. Response to letter regarding article, "revascularization decisions in patients with stable angina and intermediate lesions: results of the international survey on interventional strategy". *Circ Cardiovasc Interv*. 2015 Feb;8(2):e002296.
 89. Toth GG, Ntalianis A, Ntarladimas Y, de Booi M, De Winter O, **Barbato E**, Pilet B, Van Mieghem C, Wijns W, De Bruyne B. Effective radiation doses associated with non-invasive versus invasive assessment of coronary anatomy and physiology. *Catheter Cardiovasc Interv*. 2015 Jun;85(7):1173-81.
 90. **Barbato E**, Sarno G, Berza CT, Di Gioia G, Bartunek J, Vanderheyden M, Di Serafino L, Wijns W, Trimarco B, De Bruyne B. Impact of alpha- and beta-adrenergic receptor blockers on fractional flow reserve and index of microvascular resistance. *J Cardiovasc Transl Res*. 2014 Dec;7(9):803-9.
 91. Toth GG, Toth B, Johnson NP, De Vroey F, Di Serafino L, Pyxaras S, Rusinaru D, Di Gioia G, Pellicano M, **Barbato E**, Van Mieghem C, Heyndrickx GR, De Bruyne B, Wijns W. Revascularization decisions in patients with stable angina and intermediate lesions: results of the international survey on interventional strategy. *Circ Cardiovasc Interv*. 2014 Dec;7(6):751-9.
 92. Johnson NP, Tóth GG, Lai D, Zhu H, Açar G, Agostoni P, Appelman Y, Arslan F, **Barbato E**, Chen SL, Di Serafino L, Domínguez-Franco AJ, Dupouy P, Esen AM, Esen OB, Hamilos M, Iwasaki K, Jensen LO, Jiménez-Navarro MF, Katritsis DG, Kocaman SA, Koo BK, López-Palop R, Lorin JD, Miller LH, Muller O, Nam CW, Oud N, Puymirat E, Rieber J, Rioufol G, Rodés-Cabau J, Sedlis SP, Takeishi Y, Tonino PA, Van Belle E, Verna E, Werner GS, Fearon WF, Pijls NH, De Bruyne B, Gould KL. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. *J Am Coll Cardiol*. 2014 Oct 21;64(16):1641-54.
 93. De Bruyne B, Fearon WF, Pijls NH, **Barbato E**, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nüesch E, Jüni P; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. *N Engl J Med*. 2014 Sep 25;371(13):1208-17.
 94. Di Serafino L, Borgia F, Maeremans J, Pyxaras SA, De Bruyne B, Wijns W, Heyndrickx G, Dens J, Di Mario C, **Barbato E**. The age, creatinine, and ejection fraction score to risk stratify patients who underwent percutaneous coronary intervention of coronary chronic total occlusion. *Am J Cardiol*. 2014 Oct 15;114(8):1158-64.
 95. **Barbato E**, Salinger-Martinovic S, Sagic D, Beleslin B, Vrolix M, Neskovic AN, Jagic N, Verheye S, Mehmedbegovic Z, Wijns W. A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study. *EuroIntervention*. 2015 Sep;11(5):541-8.
 96. Tu S, **Barbato E**, Kőszegi Z, Yang J, Sun Z, Holm NR, Tar B, Li Y, Rusinaru D, Wijns W, Reiber JH. Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries. *JACC Cardiovasc Interv*. 2014 Jul;7(7):768-77.
 97. Di Gioia G, Toth G, Rusinaru D, Pellicano M, Wijns W, De Bruyne B, **Barbato E**. Acute coronary syndromes in patients with multivessel disease: the key role of optical coherence tomography. *J Cardiovasc Med (Hagerstown)*. 2016 Dec;17 Suppl 2:e112-e115.
 98. Fearon WF, Shilane D, Pijls NH, Boothroyd DB, Tonino PA, **Barbato E**, Juni P, De Bruyne B, Hlatky MA; FAME 2 Investigators. Response to letter regarding article, "Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve". *Circulation*. 2014 Jun 24;129(25):e684.
 99. Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys MJ, Magne J, **Barbato E**, Wijns W. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. *EuroIntervention*. 2014 Jun;10(2):204-11.

100. Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, **Barbato E**, Carrie D, Ando K, Merkely B, Kornowski R, Eltchaninoff H, James S, Wijns W; CENTURY II Investigators. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. *Eur Heart J*. 2014 Aug 7;35(30):2021-31.
101. Peace AJ, Mangiacapra F, Bailleul E, Delrue L, Dierickx K, Conte M, Puymirat E, Fraeymans AL, Meeus P, Bartunek J, Volpe M, **Barbato E**. α 2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant. *Arterioscler Thromb Vasc Biol*. 2014 Jun;34(6):1314-9.
102. **Barbato E**, Lara-Pezzi E, Stolen C, Taylor A, Barton PJ, Bartunek J, Iazzo P, Judge DP, Kirshenbaum L, Blaxall BC, Terzic A, Hall JL. Advances in induced pluripotent stem cells, genomics, biomarkers, and antiplatelet therapy highlights of the year in JCTR 2013. *J Cardiovasc Transl Res*. 2014 Jul;7(5):518-25.
103. Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, Di Serafino L, Muller O, Van Mieghem C, Wyffels E, Heyndrickx GR, Bartunek J, Vanderheyden M, **Barbato E**, Wijns W, De Bruyne B. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. *Eur Heart J*. 2014 Oct 21;35(40):2831-8.
104. **Barbato E**, Wijns W. Bioresorbable coronary scaffolds: a novel device-based solution in search of its clinical need. *Eur Heart J*. 2014 Mar;35(12):753-7.
105. Mangiacapra F, Cavallari I, **Barbato E**, Ricottini E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. *Am J Cardiol*. 2014 Apr 1;113(7):1124-9.
106. Pyxaras SA, Mangiacapra F, Wijns W, Di Serafino L, De Vroey F, Toth G, Sinagra G, De Bruyne B, Heyndrickx GR, **Barbato E**. ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. *Catheter Cardiovasc Interv*. 2014 Jun 1;83(7):1067-73.
107. **Barbato E**, Wijns W. Transcatheter aortic valve replacement in patients with aortic stenosis and left ventricular dysfunction: patient selection counts more than ever! *Circ Cardiovasc Interv*. 2013 Dec;6(6):596-8.
108. Di Serafino L, Sarma J, Dierickx K, Ntarladimas I, Pyxaras SA, Delrue L, De Bruyne B, Wijns W, **Barbato E**, Bartunek J. Monocyte-platelets aggregates as cellular biomarker of endothelium-dependent coronary vasomotor dysfunction in patients with coronary artery disease. *J Cardiovasc Transl Res*. 2014 Feb;7(1):1-8.
109. Maeremans J, Selleslagh P, Di Serafino L, **Barbato E**, Dens J. Impact of negative lesion characteristics of chronic total occlusions on procedural outcome and strategy. *Acta Cardiol*. 2013 Oct;68(5):455-61.
110. Pyxaras SA, Tu S, **Barbato E**, Wyffels E, Reiber JH, Wijns W. Co-registration of fractional flow reserve and optical coherence tomography with the use of a three-dimensional angiographic roadmap: an opportunity for optimisation of complex percutaneous coronary interventions. *EuroIntervention*. 2013 Nov;9(7):889.
111. Pyxaras SA, Tu S, **Barbato E**, Barbati G, Di Serafino L, De Vroey F, Toth G, Mangiacapra F, Sinagra G, De Bruyne B, Reiber JH, Wijns W. Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: comparison with fractional flow reserve. *Am Heart J*. 2013 Dec;166(6):1010-1018.e1.
112. Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, **Barbato E**. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease. *Arch Cardiovasc Dis*. 2013 Nov;106(11):554-61.
113. **Barbato E**, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W. Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial. *J Cardiovasc Transl Res*. 2014 Mar;7(2):226-31.
114. Mangiacapra F, **Barbato E**. Letter by Mangiacapra and Barbato regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease". *Circ Cardiovasc Interv*. 2013 Oct 1;6(5):e65.
115. Puymirat E, **Barbato E**. Percutaneous revascularization strategies in small-vessel disease. *Ann Cardiol Angeiol (Paris)*. 2014 Feb;63(1):28-31.
116. Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Serafino L, Van Praet F, Van Mieghem C, Stockman B, Wijns W, Degrieck I, **Barbato E**. Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. *Circulation*. 2013 Sep 24;128(13):1405-11.

117. Mangiacapra F, Peace A, **Barbato E**, Patti G, Gatto L, Ricottini E, De Bruyne B, Di Sciascio G, Wijns W. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. *Platelets*. 2014;25(5):348-56.
118. Fearon WF, Shilane D, Pijls NH, Boothroyd DB, Tonino PA, **Barbato E**, Jüni P, De Bruyne B, Hlatky MA; Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2 (FAME 2) Investigators. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve. *Circulation*. 2013 Sep 17;128(12):1335-40.
119. Pyxaras SA, Tu S, **Barbato E**, Reiber JH, Wijns W. Optimization of Tryton dedicated coronary bifurcation system with coregistration of optical coherence tomography and fractional flow reserve. *JACC Cardiovasc Interv*. 2013 Jul;6(7):e39-40.
120. Di Serafino L, De Bruyne B, Mangiacapra F, Bartunek J, Agostoni P, Vanderheyden M, Scognamiglio G, Heyndrickx GR, Wijns W, **Barbato E**. Long-term clinical outcome after fractional flow reserve- versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. *Am Heart J*. 2013 Jul;166(1):110-8.
121. De Bruyne B, **Barbato E**. Quantitative assessment of the coronary microvasculature: new tools for the black box. *Circulation*. 2013 Jun 18;127(24):2378-9.
122. Muller O, Ntalianis A, Wijns W, Delrue L, Dierickx K, Auer R, Rodondi N, Mangiacapra F, Trana C, Hamilos M, Valentin E, De Bruyne B, **Barbato E**, Bartunek J. Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease. *J Cardiovasc Transl Res*. 2013 Aug;6(4):536-44.
123. Patti G, Pasceri V, Mangiacapra F, Colonna G, Vizzi V, Ricottini E, Montinaro A, D'Ambrosio A, Wijns W, **Barbato E**, Di Sciascio G; ARMYDA-8 RELOAD-ACS Investigators. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial). *Am J Cardiol*. 2013 Jul 15;112(2):162-8.
124. Tu S, Pyxaras SA, Li Y, **Barbato E**, Reiber JH, Wijns W. In vivo flow simulation at coronary bifurcation reconstructed by fusion of 3-dimensional X-ray angiography and optical coherence tomography. *Circ Cardiovasc Interv*. 2013 Apr;6(2):e15-7.
125. Di Serafino L, Pyxaras SA, Mangiacapra F, Dierickx K, Toth G, Bartunek J, De Bruyne B, Van Mieghem C, Wijns W, **Barbato E**. Influence of transradial versus transfemoral diagnostic heart catheterisation on peripheral vascular endothelial function. *EuroIntervention*. 2013 Mar;8(11):1252-8.
126. Sciarretta S, Marchitti S, Bianchi F, Moyes A, **Barbato E**, Di Castro S, Stanzione R, Cotugno M, Castello L, Calvieri C, Eberini I, Sadoshima J, Hobbs AJ, Volpe M, Rubattu S. C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. *Circ Res*. 2013 May 10;112(10):1355-64.
127. Trana C, Toth G, Wijns W, **Barbato E**. St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial). *J Cardiovasc Transl Res*. 2013 Jun;6(3):411-4.
128. Berry C, van 't Veer M, Witt N, Kala P, Bocek O, Pyxaras SA, McClure JD, Fearon WF, **Barbato E**, Tonino PA, De Bruyne B, Pijls NH, Oldroyd KG. VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in Everyday Practice): a multicenter study in consecutive patients. *J Am Coll Cardiol*. 2013 Apr 2;61(13):1421-7.
129. Pyxaras SA, Mangiacapra F, Verhamme K, Di Serafino L, De Vroey F, Toth G, Perkan A, Salvi A, Bartunek J, De Bruyne B, Wijns W, Sinagra G, **Barbato E**. Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. *Catheter Cardiovasc Interv*. 2013 Oct 1;82(4):604-11.
130. Bartunek J, **Barbato E**, Heyndrickx G, Vanderheyden M, Wijns W, Holz JB. Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. *J Cardiovasc Transl Res*. 2013 Jun;6(3):355-63.
131. Mangiacapra F, Peace AJ, Di Serafino L, Pyxaras SA, Bartunek J, Wyffels E, Heyndrickx GR, Wijns W, De Bruyne B, **Barbato E**. Intracoronary EnalaPrilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) study. *J Am Coll Cardiol*. 2013 Feb 12;61(6):615-21.
132. Mangiacapra F, **Barbato E**. Clinical implications of platelet-vessel interaction. *J Cardiovasc Transl Res*. 2013 Jun;6(3):310-5.
133. Pyxaras SA, Sinagra G, Mangiacapra F, Perkan A, Di Serafino L, Vitrella G, Rakar S, De Vroey F, Santangelo S, Salvi A, Toth G, Bartunek J, De Bruyne B, Wijns W, **Barbato E**. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment. *Am J Cardiol*. 2013 Mar 1;111(5):684-8.

134. Muller O, Bartunek J, Hamilos M, Berza CT, Mangiacapra F, Ntalianis A, Vercruyssen K, Duby C, Wijns W, De Bruyne B, Heyndrickx GR, Vanderheyden M, Holz JB, **Barbato E**. von Willebrand factor inhibition improves endothelial function in patients with stable angina. *J Cardiovasc Transl Res*. 2013 Jun;6(3):364-70.
135. Muller O, Pyxaras SA, Trana C, Mangiacapra F, **Barbato E**, Wijns W, Taylor CA, De Bruyne B. Pressure-diameter relationship in human coronary arteries. *Circ Cardiovasc Interv*. 2012 Dec;5(6):791-6.
136. Mangiacapra F, Bartunek J, Bijnens N, Peace AJ, Dierickx K, Bailleul E, Di Serafino L, Pyxaras SA, Fraeyman A, Meeus P, Rutten M, De Bruyne B, Wijns W, van de Vosse F, **Barbato E**. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. *J Thromb Haemost*. 2012 Dec;10(12):2452-61.
137. De Bruyne B, Pijls NH, Kalesan B, **Barbato E**, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med*. 2012 Sep 13;367(11):991-1001.
138. Mangiacapra F, Patti G, **Barbato E**, Orlic D, Peace AJ, D'Ambrosio A, Ostojic M, Wijns W, Di Sciascio G. Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study. *Int J Cardiol*. 2012 Oct 18;160(3):213-4.
139. **Barbato E**, Bartunek J, Mangiacapra F, Sciarretta S, Stanzione R, Delrue L, Cotugno M, Marchitti S, Iaccarino G, Sirico G, Di Castro S, Evangelista A, Lambrechts D, Sinnaeve P, De Bruyne B, Van De Werf F, Janssens S, Fox KA, Wijns W, Volpe M, Rubattu S. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. *J Am Coll Cardiol*. 2012 May 15;59(20):1763-70.
140. Sillano D, Resmini C, Meliga E, Boccuzzi G, Zuffi A, **Barbato E**, Gunn J, Price M, Gaita F, Sheiban I. Retrospective multicenter observational study of the interventional management of coronary disease in the very elderly: the NINETY. *Catheter Cardiovasc Interv*. 2013 Sep 1;82(3):414-21.
141. Mangiacapra F, Patti G, **Barbato E**, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. *JACC Cardiovasc Interv*. 2012 Mar;5(3):281-9.
142. Mangiacapra F, De Bruyne B, Peace AJ, Melikian N, Wijns W, **Barbato E**. High cholesterol levels are associated with coronary microvascular dysfunction. *J Cardiovasc Med (Hagerstown)*. 2012 Jul;13(7):439-42.
143. Puymirat E, Peace A, Mangiacapra F, Conte M, Ntarladimas Y, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, **Barbato E**. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. *Circ Cardiovasc Interv*. 2012 Feb 1;5(1):62-8.
144. Mangiacapra F, Heyndrickx GR, Puymirat E, Peace AJ, Wijns W, De Bruyne B, **Barbato E**. Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions. *Int J Cardiol*. 2012 Feb 9;154(3):373-6.
145. **Barbato E**, Bartunek J, Marchitti S, Mangiacapra F, Stanzione R, Delrue L, Cotugno M, Di Castro S, De Bruyne B, Wijns W, Volpe M, Rubattu S. NT-proANP circulating level is a prognostic marker in stable ischemic heart disease. *Int J Cardiol*. 2012 Mar 8;155(2):311-2.
146. Wijns W, **Barbato E**. Reperfusion strategies for acute coronary syndrome. *J Cardiovasc Med (Hagerstown)*. 2011 Dec;12(12):849.
147. Puymirat E, Mangiacapra F, Peace A, Sharif F, Conte M, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, **Barbato E**. Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. *Am Heart J*. 2011 Nov;162(5):907-13.
148. Muller O, Mangiacapra F, Ntalianis A, Verhamme KM, Trana C, Hamilos M, Bartunek J, Vanderheyden M, Wyffels E, Heyndrickx GR, van Rooij FJ, Witteman JC, Hofman A, Wijns W, **Barbato E**, De Bruyne B. Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. *JACC Cardiovasc Interv*. 2011 Nov;4(11):1175-82.
149. Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, **Barbato E**, Merkely B, Edes I, Ostojic M, Wijns W, Di Sciascio G. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. *J Am Coll Cardiol*. 2011 Oct 4;58(15):1592-9.
150. Muller O, Delrue L, Hamilos M, Vercauteren S, Ntalianis A, Trana C, Mangiacapra F, Dierickx

- K, De Bruyne B, Wijns W, Behfar A, **Barbato E**, Terzic A, Vanderheyden M, Bartunek J. Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction. *EuroIntervention*. 2011 Aug;7(4):458-66.
151. Peace A, De Bruyne B, **Barbato E**. The reconciliation of pressure and light: a clinical case of complementary use of fractional flow reserve and optical coherence tomography. *J Cardiovasc Med (Hagerstown)*. 2011 Aug;12(8):571-7.
152. Mangiacapra F, **Barbato E**. From SYNTAX to FAME, a paradigm shift in revascularization strategies: the key role of fractional flow reserve in guiding myocardial revascularization. *J Cardiovasc Med (Hagerstown)*. 2011 Aug;12(8):538-42.
153. **Barbato E**. Treatment of diabetic patients with non-ST-elevation myocardial infarction. *J Cardiovasc Med (Hagerstown)*. 2011 Apr;12(4):268-9.
154. Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, Mangiacapra F, Dierickx K, Meeus P, Cuisset T, De Bruyne B, Wijns W, **Barbato E**. Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. *J Thromb Thrombolysis*. 2011 Jul;32(1):64-71.
155. Mangiacapra F, Di Serafino L, **Barbato E**. The role of fractional flow reserve to guide stent implantation. *Minerva Cardioangiol*. 2011 Feb;59(1):39-48.
156. **Barbato E**, Wijns W. Autologous cell therapy for enhanced endovascular repair after coronary stent implantation. *EuroIntervention*. 2011 Feb;6(7):794-7.
157. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E, Hamilos M, Mangiacapra F, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne B. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. *JACC Cardiovasc Interv*. 2010 Dec;3(12):1274-81.
158. Mangiacapra F, Peace AJ, Wijns W, **Barbato E**. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. *J Thromb Thrombolysis*. 2011 Jul;32(1):54-8.
159. Mangiacapra F, Muller O, Ntalianis A, Trana C, Heyndrickx GR, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, **Barbato E**. Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. *Am J Cardiol*. 2010 Nov 1;106(9):1208-11.
160. van der Schaaf RJ, Claessen BE, Hoebbers LP, Verouden NJ, Koolen JJ, Suttorp MJ, **Barbato E**, Bax M, Strauss BH, Olivecrona GK, Tuseth V, Glogar D, Råmunddal T, Tijssen JG, Piek JJ, Henriques JP; EXPLORE investigators. Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. *Trials*. 2010 Sep 21;11:89.
161. Ntalianis A, Trana C, Muller O, Mangiacapra F, Peace A, De Backer C, De Block L, Wyffels E, Bartunek J, Vanderheyden M, Heyse A, Van Durme F, Van Driessche L, De Jans J, Heyndrickx GR, Wijns W, **Barbato E**, De Bruyne B. Effective radiation dose, time, and contrast medium to measure fractional flow reserve. *JACC Cardiovasc Interv*. 2010 Aug;3(8):821-7.
162. Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Muller O, **Barbato E**, Di Sciascio G. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. *Am J Cardiol*. 2010 Sep 1;106(5):619-23.
163. Mangiacapra F, Wijns W, De Luca G, Muller O, Trana C, Ntalianis A, Heyndrickx G, Vanderheyden M, Bartunek J, De Bruyne B, **Barbato E**. Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: a real-world registry. *Catheter Cardiovasc Interv*. 2010 Jul 1;76(1):70-6.
164. Serruys PW, Garg S, Abizaid A, Ormiston J, Windecker S, Verheye S, Dubois C, Stewart J, Hauptmann KE, Schofer J, Stangl K, Witzenbichler B, Wiemer M, Barbato E, de Vries T, den Driever AM, Otake H, Meredith L, Toyloy S, Fitzgerald P. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. *EuroIntervention*. 2010 Jun;6(2):195-205.
165. Mangiacapra F, **Barbato E**. Residual platelet reactivity: predicting short-and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. *Biomark Med*. 2010 Jun;4(3):421-34.
166. Muller O, **Barbato E**, De Bruyne B, Bartunek J. Biomarkers of vulnerable plaque: the missing link with ischemia. *Biomark Med*. 2010 Jun;4(3):375-83.
167. Mangiacapra F, **Barbato E**, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciascio G. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv*. 2010 Mar;3(3):318-23.
168. Cuisset T, Hamilos M, Delrue M, Frère C, Verhamme K, Bartunek J, Saut N, Bonnet JL, Eijgelsheim M, Wijns W, Alessi MC, **Barbato E**. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in

- acute coronary syndrome. *Thromb Haemost*. 2010 Apr;103(4):774-9.
169. Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, **Barbato E**. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv*. 2010 Jan;3(1):35-40.
 170. Muller O, Hamilos M, Bartunek J, Ulrichs H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De Bruyne B, Wijns W, **Barbato E**. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol*. 2010 Feb 1;105(3):333-8.
 171. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, Ntalianis A, Muller O, **Barbato E**, Beleslin B, Sagic D, De Bruyne B, Bartunek J, Wijns W. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. *Circ Cardiovasc Interv*. 2008 Dec;1(3):193-200.
 172. Hamilos M, Muller O, Cuisset T, Ntalianis A, Chlouverakis G, Sarno G, Nelis O, Bartunek J, Vanderheyden M, Wyffels E, **Barbato E**, Heyndrickx GR, Wijns W, De Bruyne B. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. *Circulation*. 2009 Oct 13;120(15):1505-12.
 173. **Barbato E**. Role of adrenergic receptors in human coronary vasomotion. *Heart*. 2009 Apr;95(7):603-8.
 174. **Barbato E**, Rubattu S, Bartunek J, Berni A, Sarno G, Vanderheyden M, Delrue L, Zardi D, Pace B, De Bruyne B, Wijns W, Volpe M. Human coronary atherosclerosis modulates cardiac natriuretic peptide release. *Atherosclerosis*. 2009 Sep;206(1):258-64.
 175. Ciampi Q, Borzillo G, **Barbato E**, Petruzzello B, Betocchi S, Villari B. Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients. *Scand Cardiovasc J*. 2009 Feb;43(1):17-23.
 176. Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, Vanderheyden M, Barbato E, Bartunek J, De Bruyne B, Wijns W. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. *Am J Cardiol*. 2008 Jun 15;101(12):1700-3.
 177. Brevetti G, Piscione F, Cirillo P, Galasso G, Schiano V, **Barbato E**, Scopacasa F, Chiariello M. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. *Atherosclerosis*. 2008 Dec;201(2):440-6.
 178. Cuisset T, Hamilos M, Melikian N, Wyffels E, Sarma J, Sarno G, **Barbato E**, Bartunek J, Wijns W, De Bruyne B. Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. *J Am Coll Cardiol*. 2008 Mar 18;51(11):1060-5.
 179. De Bruyne B, **Barbato E**. Drug-eluting stent implantation: technique matters, more than ever. *JACC Cardiovasc Interv*. 2008 Feb;1(1):32-3.
 180. **Barbato E**, Penicka M, Delrue L, Van Durme F, De Bruyne B, Goethals M, Wijns W, Vanderheyden M, Bartunek J. Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy. *Heart*. 2007 Jul;93(7):856-61.
 181. **Barbato E**, Berger A, Delrue L, Van Durme F, Manoharan G, Boussy T, Heyndrickx GR, De Bruyne B, Ciampi Q, Vanderheyden M, Wijns W, Bartunek J. GLU-27 variant of beta2-adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease. *Atherosclerosis*. 2007 Oct;194(2):e80-6.
 182. Manoharan G, Pijls NH, Lameire N, Verhamme K, Heyndrickx GR, **Barbato E**, Wijns W, Madaric J, Tielbee X, Bartunek J, De Bruyne B. Assessment of renal flow and flow reserve in humans. *J Am Coll Cardiol*. 2006 Feb 7;47(3):620-5.
 183. Aarnoudse W, Geven M, **Barbato E**, Botman KJ, De Bruyne B, Pijls NH. Effect of phentolamine on the hyperemic response to adenosine in patients with microvascular disease. *Am J Cardiol*. 2005 Dec 15;96(12):1627-30.
 184. De Luca G, Suryapranata H, Piscione F, **Barbato E**, Chiariello M. Stenting and abciximab in primary angioplasty: a review of current status. *Ital Heart J*. 2005 Nov;6(11):874-80.
 185. **Barbato E**, De Bruyne B, MacCarthy P, Pijls NH, De Luca G, Volpe M. Functional assessment of coronary atherosclerosis in the catheterization laboratory: the key role of fractional flow reserve. *Ital Heart J*. 2005 Jul;6(7):549-56.
 186. **Barbato E**, Wijns W, De Bruyne B, Mascia G, Piscione F. [Current concepts of the physiopathology of coronary beta-adrenergic receptors, and their clinical applications]. *Recenti Prog Med*. 2005 Sep;96(9):411-5.
 187. Iaccarino G, **Barbato E**, Cipolletta E, De Amicis V, Margulies KB, Leosco D, Trimarco B, Koch WJ. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. *Eur Heart J*. 2005 Sep;26(17):1752-8.
 188. MacCarthy P, Berger A, Manoharan G, Bartunek J, **Barbato E**, Wijns W, Heyndrickx GR, Pijls NH, De Bruyne B. Pressure-derived measurement of coronary flow reserve. *J Am Coll Cardiol*.

- 2005 Jan 18;45(2):216-20.
189. **Barbato E**, Piscione F, Bartunek J, Galasso G, Cirillo P, De Luca G, Iaccarino G, De Bruyne B, Chiariello M, Wijns W. Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. *Circulation*. 2005 Jan 25;111(3):288-94.
 190. **Barbato E**, Bartunek J, Aarnoudse W, Vanderheyden M, Staelens F, Wijns W, Heyndrickx GR, Pijls NH, De Bruyne B. Alpha-adrenergic receptor blockade and hyperaemic response in patients with intermediate coronary stenoses. *Eur Heart J*. 2004 Nov;25(22):2034-9.
 191. **Barbato E**, Aarnoudse W, Aengevaeren WR, Werner G, Klauss V, Bojara W, Herzfeld I, Oldroyd KG, Pijls NH, De Bruyne B; Week 25 study group. Validation of coronary flow reserve measurements by thermodilution in clinical practice. *Eur Heart J*. 2004 Feb;25(3):219-23.
 192. Penicka M, Bartunek J, Wijns W, De Wolf I, Heyndrickx GR, De Raedt H, **Barbato E**, De Bruyne B. Tissue doppler imaging predicts recovery of left ventricular function after recanalization of an occluded coronary artery. *J Am Coll Cardiol*. 2004 Jan 7;43(1):85-91.
 193. **Barbato E**, Bartunek J, Wyffels E, Wijns W, Heyndrickx GR, De Bruyne B. Effects of intravenous dobutamine on coronary vasomotion in humans. *J Am Coll Cardiol*. 2003 Nov 5;42(9):1596-601.
 194. De Bruyne B, Pijls NH, **Barbato E**, Bartunek J, Bech JW, Wijns W, Heyndrickx GR. Intracoronary and intravenous adenosine 5'-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. *Circulation*. 2003 Apr 15;107(14):1877-83.
 195. **Barbato E**, Marco J, Wijns W. Direct stenting. *Eur Heart J*. 2003 Mar;24(5):394-403.
 196. Pijls NH, De Bruyne B, Smith L, Aarnoudse W, **Barbato E**, Bartunek J, Bech GJ, Van De Vosse F. Coronary thermodilution to assess flow reserve: validation in humans. *Circulation*. 2002 May 28;105(21):2482-6.
 197. Piscione F, **Barbato E**, Galasso G, Chiariello M. [Diabetes and ischemic cardiopathy]. *Ital Heart J Suppl*. 2001 Sep;2(9):980-9.
 198. Iaccarino G, **Barbato E**, Cipoletta E, Esposito A, Fiorillo A, Koch WJ, Trimarco B. Cardiac betaARK1 upregulation induced by chronic salt deprivation in rats. *Hypertension*. 2001 Aug;38(2):255-60.
 199. Iaccarino G, **Barbato E**, Cipoletta E, Fiorillo A, Trimarco B. Role of the sympathetic nervous system in cardiac remodeling in hypertension. *Clin Exp Hypertens*. 2001 Jan-Feb;23(1-2):35-43.
 200. Lembo G, Morisco C, Lanni F, **Barbato E**, Vecchione C, Fratta L, Trimarco B. Systemic hypertension and coronary artery disease: the link. *Am J Cardiol*. 1998 Aug 6;82(3A):2H-7H.
 201. Lembo G, Iaccarino G, Vecchione C, **Barbato E**, Morisco C, Monti F, Parrella L, Trimarco B. Insulin enhances endothelial alpha2-adrenergic vasorelaxation by a pertussis toxin mechanism. *Hypertension*. 1997 Nov;30(5):1128-34.
 202. Lembo G, Iaccarino G, Vecchione C, **Barbato E**, Izzo R, Fontana D, Trimarco B. Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm. *J Clin Invest*. 1997 Oct 15;100(8):2007-14.
 203. Sarno D, Argenziano L, Morisco C, Monti F, **Barbato E**, Fratta L, Trimarco B. [A new cardiovascular risk factor: heart rate]. *Cardiologia*. 1995 Dec;40(12 Suppl 1):297-9.

Scopus: H-index: 48; Citations: 11508

CAPITOLI IN LIBRI

- 1) **BARBATO E**, Wijns W. Direct stenting versus pre-dilatation stenting. Chapter in *The Year in Interventional Cardiology 2003*, Banning AP, De Feyter PJ. Ed. Clinical Publishing
- 2) **BARBATO E**, Colombo A, Heyndrickx GHR. Interventional technology: rotational atherectomy. **PCR-EAPCI Textbook 2012**
- 3) Di Serafino L, **BARBATO E**. Drug eluting stents with bioresorbable polymer: the menu. **Minerva Cardioangiologica Ed. 2012**

CONFERENCE E SEMINARI

- Course Director of the "13th Rotablator workshop" (Aalst, Belgium – 2018)
- Course Director of the "13th and 14th OCT workshop" (Aalst/Leuven, Belgium – 2017)
- Course Director of the "11th and 12th Rotablator workshop" (Aalst, Belgium – 2017)
- Course Director of the "10th, 11th and 12th OCT workshop" (Aalst/Leuven, Belgium – 2016)
- Course Director of the "9th and 10th Rotablator workshop" (Aalst, Belgium – 2016)
- Course Director of the "8th and 9th OCT workshop" (Aalst/Leuven, Belgium – 2015)
- Course Director of the "Fourth Joint Cardiology Seminar at Academia Belgica" (Rome, Italy – 2015)

Course Director of the “7th and 8th Rotablator workshop” (Aalst, Belgium – 2015)
Course Director of the “6th and 7th OCT workshop” (Aalst/Leuven, Belgium – 2014)
Course Director of the “5th and 6th Rotablator workshop” (Aalst, Belgium – 2014)
Course Director of the “Third Joint Cardiology Seminar at Academia Belgica” (Rome, Italy – 2013)
Course co-Director of the “Coronary Physiology in the Cathlab” (Catanzaro, Italy – 2013)
Course Director of the “4th and 5th OCT workshop” (Leuven, Belgium – 2013)
Course Director of the “4th Rotablator workshop” (Aalst, Belgium – 2013)
Course Director of the “CTO workshop” (Aalst, Belgium - 2013)
Course Director of the “Second Joint Cardiology Seminar at Academia Belgica” (Rome, Italy – 2012)
Course Director of the “3rd Rotablator workshop” (Aalst, Belgium – 2012)
Course Director of the “3rd OCT workshop” (Aalst, Belgium – 2012)
Course Director of the “2nd OCT workshop” (Leuven, Belgium – 2012)
Course Director of the “2nd Rotablator workshop” (Aalst, Belgium – 2011)
Course Director of the “1st OCT workshop” (Aalst, Belgium – 2012)
Course Director of the “First Joint Cardiology Seminar at Academia Belgica” (Rome, Italy – 2010)

Autorizzazione al trattamento dei dati personali in conformità al Decreto legislativo 196/03 e s.m.i.

Autorizzo il trattamento dei dati personali ai sensi del Decreto legislativo 196/03 e s.m.i. in materia di privacy.

In fede,

Firma _____

Autocertificazione ai sensi degli artt. 46, 47 e 76 del D.P.R. n. 445/2000

Io sottoscritto EMANUELE BARBATO, nato a TEVEROLA (CE) il 09/04/1972 e residente in TEVEROLA (CE), consapevole delle conseguenze penali derivanti da dichiarazioni false e mendaci, come disposto dall'art. 76 del D.P.R. n. 445/2000, attesto che tutto quanto riportato nel curriculum corrisponde a verità.

NAPOLI, 8/10/2019

In fede.

Firma _____